痛苦
受体
医学
胰高血糖素样肽-1
减肥
肥胖
生物信息学
生物
内分泌学
内科学
糖尿病
2型糖尿病
政治学
政治
法学
作者
Iona Davies,Tricia Tan
标识
DOI:10.1080/17460441.2023.2203911
摘要
Introduction With obesity rates growing globally, there is a paramount need for new obesity pharmacotherapies to tackle this pandemic.Areas covered This review focuses on the design of therapeutics that target the glucose-dependent insulinotropic polypeptide receptor (GIPR) to aid weight loss. The authors highlight the paradoxical observation that both GIPR agonism and antagonism appear to provide metabolic benefits when combined with glucagon-like peptide-1 receptor (GLP-1 R) agonism. The therapeutic potential of compounds that target the GIPR alongside the GLP-1 R and the glucagon receptor are discussed, and the impressive clinical findings of such compounds are reviewed.Expert opinion In this area, the translation of pre-clinical findings to clinical studies appears to be particularly difficult. Well-designed physiological studies in man are required to answer the paradox highlighted above, and to support the safe future development of a combination of GLP-1 R/GIPR targeting therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI